Superior Planning, LLC’s Syndax Pharmaceuticals SNDX Stock Holding History

Superior Planning, LLC’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$734	Buy	+39	New	+$788	﹤0.01%	1825

Other funds holding SNDX

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $77.1B AUM 11.99% 1-Year Est. Return

Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return

Superior Planning, LLC's SNDX Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Syndax Pharmaceuticals (SNDX) in Q3 2026: 39 shares worth $734. The stake represents ﹤0.01% of the portfolio and ranks #1825 among its holdings.

124 funds tracked by Wall St. Rank hold SNDX as of Q3 2026.

Superior Planning, LLC held 39 shares of Syndax Pharmaceuticals worth $734 as of Q3 2026.
Syndax Pharmaceuticals was a new Superior Planning, LLC position in Q3 2026.
Syndax Pharmaceuticals made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1825 holding.
124 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.